Vertex (VRTX) | Stock Overview & Key Data
Vertex Performance Comparison
Stock Range
Today's Range
Low: $388.71
High: $395.76
on August 15, 2025
52 Week Range
Low: $362.50
High: $519.88
on August 11, 2025
on November 8, 2024
All-Time High: $519.88 on November 4, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$100.4B
EPS
14.06
P/E Ratio (TTM)
27.85
Forward P/E
20.86
P/B Ratio
5.84
PEG Ratio
-0.22
Div. Yield
N/A
ROE
22.77%
Beta
0.444
Debt to Equity
8.89
Financial Highlights
Profitability
Gross Margin
86.25%
Operating Margin
38.93%
Profit Margin
31.86%
Returns and Earnings
Return on Assets (TTM)
13.09%
Return on Equity (TTM)
22.77%
EBITDA
$485.8M
Net Income (TTM)
$3.6B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$44.44
Quarterly Revenue Growth (YoY)
12.10%
Quarterly Earnings Growth (YoY)
12.06%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Vertex VRTX | 100.38B Large-cap | 7.15% | -15.40% | -9.59% | -15.01% | -3.21% | -17.72% | 31.35% | 44.79% |
| Regeneron REGN | 58.99B Large-cap | 3.09% | 5.92% | -0.78% | -14.65% | -18.85% | -50.78% | -6.14% | -4.14% |
| Alnylam ALNY | 56.35B Large-cap | 2.27% | 44.29% | 58.40% | 79.56% | 92.15% | 67.35% | 107.86% | 228.63% |
| Insmed INSM | 25.79B Large-cap | 16.66% | 24.23% | 90.12% | 57.08% | 82.70% | 67.72% | 408.56% | 370.89% |
| Royalty Pharma plc RPRX | 21.26B Large-cap | -3.27% | -0.44% | 9.75% | 10.65% | 40.95% | 33.79% | -17.57% | -13.39% |
| Incyte INCY | 15.94B Large-cap | 10.88% | 27.36% | 38.50% | 21.96% | 25.01% | 39.83% | 16.61% | -7.64% |
Ownership & Short Interest
Insider Ownership
0.14%
Institutional Ownership
99.81%
Shares Short
4M
Short Ratio
4.04
Short % of Shares Outstanding
1.92%
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Vertex Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Vertex would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is VRTX's 52-week high and low?
- In the last 52 weeks, Vertex reached a high of $519.88 (on November 8, 2024) and a low of $362.50 (on August 11, 2025).
- What is the market cap and P/E ratio for VRTX?
- Curious about Vertex's size and valuation? Its market capitalization stands at 100.38B. When it comes to valuation, the P/E ratio (trailing twelve months) is 27.85, and the forward P/E (looking ahead) is 20.86.
- Does VRTX pay dividends? If so, what's the yield?
- As for dividends, Vertex isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Vertex's main competitors or similar companies to consider before investing?
When looking at Vertex, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Regeneron
REGN58.99B Healthcare Biotechnology -50.78% -6.14% Alnylam
ALNY56.35B Healthcare Biotechnology 67.35% 107.86% Insmed
INSM25.79B Healthcare Biotechnology 67.72% 408.56% Royalty Pharma plc
RPRX21.26B Healthcare Biotechnology 33.79% -17.57% Incyte
INCY15.94B Healthcare Biotechnology 39.83% 16.61% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Vertex Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Vertex's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 22.77%, the Debt to Equity ratio from the most recent quarter is 8.89, and its Gross Profit Margin stands at 86.25%.
- What is the recent revenue and earnings growth for VRTX?
- Looking at Vertex's growth, its revenue over the trailing twelve months (TTM) was $11B. Compared to the same quarter last year (YoY), quarterly revenue grew by 12.10%, and quarterly earnings saw a YoY growth of 12.06%.
- How much of VRTX stock is held by insiders and institutions?
- Wondering who owns Vertex stock? Company insiders (like executives and directors) hold about 0.14% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.81%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.